April 13, 2016 1:05pm
For the treatment of hematopoietic disorders – SELL on strength
- Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”: Three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells
- Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”: The use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system, such as disorders caused by exposure to radiation or chemotherapy, and failed engraftment of hematopoietic stem cell transplants.
The Bottom Line: in the Japanese market, PSTI is in active negotiations with potential pharmaceutical partners. Who, what and when … (?) The key will be the indication and their ramifications as appreciation will “wither” from just a two patent award.
The list of List of conditions treated with hematopoietic stem cell transplantation is long list which may be used to treat a number of conditions both congenital and acquired.
PSTI is UP +$0.16 to $1.69 at the mid-day in a day trading range of $1.61 to $1.72 with 359.4 K shares traded <3 month average = 262.9 K shares> - SELL on strength; it won’t last until a potential partners appear.